Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN

**************************************************************

XRX, Xerox Corp.

XRX engages in the development, manufacture, marketing, servicing, and financing of document equipment, software, solutions, and services worldwide.

XRX said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock to create a $22 billion business that combines XRX’s copiers, printers and document management services with the “business process outsourcing” of Dallas-based ACS., joining the expensive race among technology companies to broaden their offerings.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in

Nutra Pharma has announced their intention to begin the registration for their over-the-counter pain reliever in both Canada and Europe. Currently, the company is marketing a similar product, Cobroxin, within the United States. Cobroxin is used for the treatment of moderate to severe (Stage 2) chronic pain.

According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reports that chronic pain effects one in five adults across Europe.

Dr. Paul Redi, CEO of ReceptoPharm, stated, “We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe. We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those

• Merck (NYSE:MRK) announced its plans to abandon an experimental treatment for migraines and to review Phase III clinical data on another migraine drug

• Morgan Stanley's (NYSE:MS) CEO John Mack will be replaced before year-end by current co-president James Gorman

• Abbott Labs (NYSE:ABT) announced that it bought the 90% of Evalve that it does not already own for $410 million

• Bank of America (NYSE:BAC) cut its rating on Electronic Arts (NASDAQ:ERTS) to "neutral"

• Wells Fargo (NYSE:WFC) lowered its rating on AIG (NYSE:AIG) to "underperform" asserting the firm currently is trading "significantly" above book value

• National Semiconductor (NYSE:NSM) reported fiscal first quarter earnings of 13 cents a share, 6 cents above estimates on revenues of $314 million

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

Today, Nutra Pharma Corp., a biotechnology company that develops treatments for AMN, HIV and Multiple Sclerosis, announced the launch of an over-the-counter pain reliever, Cobroxin, for the treatment of Stage 2 chronic pain. Cobroxin is the first clinically approved OTC pain reliever for Stage 2 pain.

The drug, developed by Nutra Pharma’s subsidiary, ReceptoPharm, will be available as an oral spray. It is designed to treat lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia. It will also be available as a topical gel for treating repetitive stress, arthritis, and joint pain.

Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation, commented, “Cobroxin is a next generation pain reliever that addresses physician and consumer demand for a safer and less costly treatment for chronic pain. Cobroxin provides affordable and accessible pain relief for those without healthcare coverage, for those looking for a safer and effective treatment for pain,

I am not the type of investor that puts a lot of faith into weak correlations and other far flung events or crazy theories. However, after reading the news coming out of international oil giant ConocoPhillips [COP: 37.60, 0.00 (0.00%)] I started thinking. As many of you know, ConocoPhillips has taken the worst beating out of any of the oil majors since the global recession started. This isn’t earth shattering news, but what I do find interesting are the comments that are coming from management, and how it could potentially relate to one of their competitors, BP [BP: 39.35, 0.00 (0.00%)].

The reason Conoco got me thinking about BP is the stark similarities between the two majors; I believe the companies are potentially the most similar of all the oil majors. Both companies have a larger than average exposure to natural gas in relation to crude oil. In particular,

Looking at the wide variety of companies working to make a go of their business makes one wonder when and if any of them will actually make the leap from development to profitable. So many companies struggle through the year, with only a hope of breaking through. Every once in a while, however, a company makes the leap after laying out millions to get their product to market. Being willing to take the risk and invest is where the savvy investor profits. The risk remains, but it can certainly result in a nice profit.

MAP Pharmaceuticals Inc., a development stage drug company, works to develop pharmaceutical type medications primarily directed at pediatric asthma, non-pediatric asthma, migraines and diabetes. The company is more specifically involved in nebulized medications and cardiac inhaler delivery systems.

To imply that the company is more oriented toward the delivery system of the medications it develops would be